Home
This Title All WIREs
WIREs RSS Feed
How to cite this WIREs title:
WIREs Nanomed Nanobiotechnol
Impact Factor: 5.186

The need to pursue and publish clinical trials in nanomedicine

Full article on Wiley Online Library:   PDF

Can't access this content? Tell your librarian.

Related Articles

The NCI Alliance for Nanotechnology in Cancer: achievement and path forward
Nanoparticle therapeutics: a personal perspective
Sample size calculations for clinical trials (WIREs Computational Statistics )
blog comments powered by Disqus

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

Sign Up for Article Alerts

In the Spotlight

Robert Langer

Robert Langer

works at the interface of biotechnology and materials science. His lab is researching many topics, such as investigating the mechanism of release from polymeric delivery systems with concomitant microstructural analysis and mathematical modeling; studying applications of these systems including the development of effective long-term delivery systems for insulin, anti-cancer drugs, growth factors, gene therapy agents and vaccines; developing controlled release systems that can be magnetically, ultrasonically, or enzymatically triggered to increase release rates; synthesizing new biodegradable polymeric delivery systems which will ultimately be absorbed by the body; creating new approaches for delivering drugs such as proteins and genes across complex barriers such as the blood-brain barrier, the intestine, the lung and the skin; stem cell research including controlling growth and differentiation; and creating new biomaterials with shape memory or surface switching properties.

Learn More

Twitter: WIREsNanomed Follow us on Twitter